Merck & Co and Schering-Plough settle Vytorin class action suits
This article was originally published in Scrip
Executive Summary
Merck & Co and Schering-Plough have agreed to pay $41.5 million to settle all of the civil class action litigation pending against the companies relating to the purchase or use of Vytorin (ezetimibe plus simvastatin) and Zetia (ezetimibe).